| |
| |
| Dear Fellow Investor,
There's no sector poised to deliver bigger gains in 2022 than small-cap biotech stocks.
In the past year alone... - Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%.
- Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%.
- Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump.
What drives massive gains like that?
It usually comes when a biotech unveils a unique new drug.
On December 5, 2020, a small Cambridge biotech shocked the world when they could "Find & Replace" the genes that cause the disease anemia.
This revolutionary new kind of treatment may not just change sickle cell anemia -
It has the potential to eliminate genetic disease from our species.
If that sounds like science fiction, consider this - - The Nobel Prize Committee is calling it "The Holy Grail of Medicine."
- The Wall Street Journal reports the company is "transforming medicine."
- 60 Minutes reports the company is "revolutionizing the search for new drugs."
Investor's Business Daily estimates the market is worth at least $75 billion. But right now, its stock price is just a tiny fraction of that size.
That's if the company doesn't get taken over for fast 300% gains first.
Sincerely,
Dylan Jovine
CEO and Founder
Behind the Markets
| | |
| |
DISCLAIMER: This communication includes advertising material and PAID ADVERTISEMENTS provided to our customers. Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.
| | | |
Tidak ada komentar:
Posting Komentar